ACQUISITION–RELATED (GAINS) CHARGES AND PRODUCT DISCONTINUATION, NET- DepoCyte Product Discontinuance (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
DepoCyte Discontinuation [Roll Forward]
Total, Charges Incurred	$ 1,418	$ 3,405	$ (2,290)	$ 4,647
DepoCyte
DepoCyte Discontinuation [Roll Forward]
Acquisition-Related Separation Costs, Beginning Balance			81
Acquisition-Related Separation Costs, Charges Incurred			0
Acquisition-Related Separation Costs, Cash Payments Made			(81)
Acquisition-Related Separation Costs, Ending Balance	0		0
Asset Retirement Obligations, Other Restructuring and Discontinuation Costs, Beginning Balance			558
Asset Retirement Obligations, Other Restructuring and Discontinuation Costs, Charges Incurred			21
Asset Retirement Obligations, Other Restructuring and Discontinuation Costs, Cash Payments Made			(449)
Asset Retirement Obligations, Other Restructuring and Discontinuation Costs, Ending Balance	130		130
Total, Beginning Balance			639
Total, Charges Incurred			21
Total, Cash Payments Made			(530)
Total, Ending Balance	$ 130		$ 130